SUPN Q1 2021 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q1 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$131M+37.9% YoY

Gross Profit

$116M88.6% margin

Operating Income

$13M10.1% margin

Net Income

$6M4.3% margin

EPS (Diluted)

$0.11

QoQ Revenue Growth

-8.8%

Cash Flow

Operating Cash Flow

$36M

Free Cash Flow

$35M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$753M

Stockholders' Equity

$754M

Cash & Equivalents

$256M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$131M	$95M	+37.9%
Gross Profit	$116M	$91M	+27.7%
Operating Income	$13M	$29M	-54.5%
Net Income	$6M	$22M	-73.5%

Revenue Segments

Product

$128M50%

Trokendi Xr

$72M28%

Oxtellar X R

$27M11%

APOKYN

$22M8%

MYOBLOC

$4M2%

XADAGO

$3M1%

Royalty

$3M1%